New strategies in the discovery of novel non-camptothecin topoisomerase i inhibitors

Current Medicinal Chemistry

Volumn 18, Issue 28, 2011, Pages 4389-4409

  Sheng, Chunquan ^a   Miao, Zhenyuan ^a   Zhang, Wannian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Design strategy; Evodiamines; Indenoisoquinolines; Indolocarbazoles; Lamellarins; Non camptothecin; Phenanthridines; Pyridines; Structure activity relationship; Topoisomerase I inhibitors

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; 5,6 DIHYDRO 2,3 DIMETHOXY 6 METHYL 8,9 METHYLENEDIOXY 5,11 DIOXO 11H INDENO[1,2 C]ISOQUINOLINE; 6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; 6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; A 61276; AMPELOPSISIONOSIDE; ARC 111; ARC 31; BENZIMIDAZOLE DERIVATIVE; BERBERINE DERIVATIVE; BMS 210287; BMS 250749; BMS 251873; CALOTHRIXIN B; CAMPTOTHECIN DERIVATIVE; CARBAZOLE DERIVATIVE; CUCURBITACIN; DNA TOPOISOMERASE INHIBITOR; ED 709; EDOTECARIN; EVODIAMINE; INDOLE DERIVATIVE; LAMELLARIN D; MAURITIANIN; NAPHTHYRIDINE DERIVATIVE; NATURAL PRODUCT; NSC 724998; NSC 725776; NSC 727357; PLANT MEDICINAL PRODUCT; PLUKENETIONE A; PYRROLO[2,1 A]ISOQUINOLINE DERIVATIVE; REBECCAMYCIN; SAUCERNEOL D; SEMPERVIRINE; SYRINGARESINOL; TSITSIKAMMAMINE A; TSITSIKAMMAMINE B; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAKAYIN; XR 11576;

ANTINEOPLASTIC ACTIVITY; CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

CARBAZOLES; DNA TOPOISOMERASES, TYPE I; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; HUMANS; ISOQUINOLINES; PHENANTHRIDINES; PYRIDINES; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE I INHIBITORS;

EID: 80052937351     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797200453     Document Type: Review

References (168)

1. Champoux, J.J., DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem., 2001, 70, 369-413. (Pubitemid 32662215)
2. Pommier, Y.; Barcelo, J.M.; Rao, V.A.; Sordet, O.; Jobson, A.G.; Thibaut, L.; Miao, Z.H.; Seiler, J.A.; Zhang, H.; Marchand, C.; Agama, K.; Nitiss, J.L.; Redon, C., Repair of topoisomerase I-mediated DNA damage. Prog. Nucleic Acid Res. Mol. Biol., 2006, 81, 179-229. (Pubitemid 44767505)
3. Pommier, Y., DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem. Rev., 2009, 109, 2894-2902.
4. Pommier, Y., Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer, 2006, 6, 789-802. (Pubitemid 44450467)
5. Nitiss, J.L., DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer, 2009, 9, 327-337.
6. Beretta, G.L.; Perego, P.; Zunino, F., Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors. Expert. Opin. Ther. Targets, 2008, 12, 1243-1256.
7. Nitiss, J.L., Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer, 2009, 9, 338-350.
8. Tse, Y.C.; Kirkegaard, K.; Wang, J.C., Covalent bonds between protein and DNA. Formation of phosphotyrosine linkage between certain DNA topoisomerases and DNA. J. Biol. Chem., 1980, 255, 5560-5565.
9. Hsiang, Y.H.; Hertzberg, R.; Hecht, S.; Liu, L.F., Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 1985, 260, 14873-14878. (Pubitemid 16211028)
10. Wall, M.E.; Wani, M.C.; Cook, C.E.; Palmer, K.H.; McPhail, A.T.; Sim, G.A., The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca Acuminata. J. Am. Chem. Soc., 1966, 88, 3888-3890.
11. D'Arpa, P.; Beardmore, C.; Liu, L.F., Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res., 1990, 50, 6919-6924. (Pubitemid 20361091)
12. Liu, L.F.; Desai, S.D.; Li, T.K.; Mao, Y.; Sun, M.; Sim, S.P., Mechanism of action of camptothecin. Ann. N. Y. Acad. Sci., 2000, 922, 1-10. (Pubitemid 32050237)
13. Tsao, Y.P.; D'Arpa, P.; Liu, L.F., The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer. Res, 1992, 52, 1823-1829.
14. Driver, R.W.; Yang, L.X., Synthesis and pharmacology of new camptothecin drugs. Mini. Rev. Med. Chem., 2005, 5, 425-439. (Pubitemid 40601634)
15. Li, Q.Y.; Zu, Y.G.; Shi, R.Z.; Yao, L.P., Review camptothecin: current perspectives. Curr. Med. Chem., 2006, 13, 2021-2039.
16. Thomas, C.J.; Rahier, N.J.; Hecht, S.M., Camptothecin: current perspectives. Bioorg. Med. Chem., 2004, 12, 1585-1604. (Pubitemid 38344159)
17. Kingsbury, W.D.; Boehm, J.C.; Jakas, D.R.; Holden, K.G.; Hecht, S.M.; Gallagher, G.; Caranfa, M.J.; McCabe, F.L.; Faucette, L.F.; Johnson, R.K., Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem., 1991, 34, 98-107.
18. Garcia-Carbonero, R.; Supko, J.G., Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res., 2002, 8, 641-661. (Pubitemid 34742090)
19. Giovanella, B.C.; Stehlin, J.S.; Hinz, H.R.; Kozielski, A.J.; Harris, N.J.; Vardeman, D.M., Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan). Int. J. Oncol., 2002, 20, 81-88.
20. Eckhardt, S.G.; Baker, S.D.; Eckardt, J.R.; Burke, T.G.; Warner, D.L.; Kuhn, J.G.; Rodriguez, G.; Fields, S.; Thurman, A.; Smith, L.; Rothenberg, M.L.; White, L.; Wissel, P.; Kunka, R.; DePee, S.; Littlefield, D.; Burris, H.A.; Von Hoff, D.D.; Rowinsky, E.K., Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks. Clin. Cancer. Res., 1998, 4, 595-604. (Pubitemid 28193557)
21. Minami, H.; Fujii, H.; Igarashi, T.; Itoh, K.; Tamanoi, K.; Oguma, T.; Sasaki, Y., Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks. Clin. Cancer Res., 2001, 7, 3056-3064. (Pubitemid 32963824)
22. Pommier, Y., Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.Curr. Med. Chem. Anticancer Agents, 2004, 4, 429-434. (Pubitemid 39199346)
23. Cinelli, M.A.; Cordero, B.; Dexheimer, T.S.; Pommier, Y.; Cushman, M., Synthesis and biological evaluation of 14-(aminoalkylaminomethyl) aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships. Bioorg. Med. Chem., 2009, 17, 7145-7155.
24. Burke, T.G., Chemistry of the camptothecins in the bloodstream. Drug stabilization and optimization of activity. Ann. N. Y. Acad. Sci., 1996, 803, 29-31. (Pubitemid 27057972)
25. Hsiang, Y.H.; Liu, L.F., Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 1988, 48, 1722-1726.
26. Brangi, M.; Litman, T.; Ciotti, M.; Nishiyama, K.; Kohlhagen, G.; Takimoto, C.; Robey, R.; Pommier, Y.; Fojo, T.; Bates, S.E., Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance halftransporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res., 1999, 59, 5938-5946. (Pubitemid 30004955)
27. Liao, Z.; Robey, R.W.; Guirouilh-Barbat, J.; To, K.K.; Polgar, O.; Bates, S.E.; Pommier, Y., Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan. Mol. Pharmacol., 2008, 73, 490-497. (Pubitemid 351159219)
28. Nakagawa, H.; Saito, H.; Ikegami, Y.; Aida-Hyugaji, S.; Sawada, S.; Ishikawa, T., Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. Cancer Lett., 2006, 234, 81-89. (Pubitemid 43343942)
29. Fujimori, A.; Harker, W.G.; Kohlhagen, G.; Hoki, Y.; Pommier, Y., Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res., 1995, 55, 1339-1346.
30. Urasaki, Y.; Laco, G.S.; Pourquier, P.; Takebayashi, Y.; Kohlhagen, G.; Gioffre, C.; Zhang, H.; Chatterjee, D.; Pantazis, P.; Pommier, Y., Characterization of a novel topoisomerase I mutation from a camptothecin- resistant human prostate cancer cell line. Cancer Res., 2001, 61, 1964-1969. (Pubitemid 32692014)
31. Khadka, D.B.; Cho, W.J., 3-Arylisoquinolines as novel topoisomerase I inhibitors. Bioorg. Med. Chem., 2011, 19, 724-734.
32. Meng, L.H.; Liao, Z.Y.; Pommier, Y., Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy. Curr. Top. Med. Chem., 2003, 3, 305-320.
33. Teicher, B.A., Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem. Pharmacol., 2008, 75, 1262-1271. (Pubitemid 351305209)
34. Pommier, Y., Diversity of DNA topoisomerases I and inhibitors. Biochimie, 1998, 80, 255-270. (Pubitemid 28206041)
35. Yamada, Y.; Tamura, T.; Yamamoto, N.; Shimoyama, T.; Ueda, Y.; Murakami, H.; Kusaba, H.; Kamiya, Y.; Saka, H.; Tanigawara, Y.; McGovren, J.P.; Natsumeda, Y., Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors. Cancer Chemother. Pharmacol., 2006, 58, 173-182.
36. Antony, S.; Jayaraman, M.; Laco, G.; Kohlhagen, G.; Kohn, K.W.; Cushman, M.; Pommier, Y., Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecinresistant topoisomerases I. Cancer Res., 2003, 63, 7428-7435. (Pubitemid 37413485)
37. Antony, S.; Kohlhagen, G.; Agama, K.; Jayaraman, M.; Cao, S.; Durrani, F.A.; Rustum, Y.M.; Cushman, M.; Pommier, Y., Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol. Pharmacol., 2005, 67, 523-530. (Pubitemid 40216745)
38. Mann, J., Natural products in cancer chemotherapy: past, present and future. Nat. Rev. Cancer, 2002, 2, 143-148. (Pubitemid 37328801)
39. Oberlies, N.H.; Kroll, D.J., Camptothecin and taxol: historic achievements in natural products research. J. Nat. Prod., 2004, 67, 129-135. (Pubitemid 38282896)
40. Ma, J.; Jones, S.H.; Marshall, R.; Wu, X.; Hecht, S.M., DNA topoisomerase I inhibitors from Rinorea anguifera. Bioorg. Med. Chem. Lett., 2005, 15, 813-816. (Pubitemid 40143171)
41. Cheng, X.; Wang, D.; Jiang, L.; Yang, D., DNA topoisomerase I inhibitory alkaloids from Corydalis saxicola. Chem. Biodivers., 2008, 5, 1335-1344.
42. Wang, P.; Li, S.; Ownby, S.; Zhang, Z.; Yuan, W.; Zhang, W.; Scott Beasley, R., Ecdysteroids and a sucrose phenylpropanoid ester from Froelichia floridana. Phytochemistry, 2009, 70, 430-436.
43. Zheng, M.S.; Lee, Y.K.; Li, Y.; Hwangbo, K.; Lee, C.S.; Kim, J.R.; Lee, S.K.; Chang, H.W.; Son, J.K., Inhibition of DNA topoisomerases I and II and cytotoxicity of compounds from Ulmus davidiana var. japonica. Arch. Pharm. Res., 2010, 33, 1307-1315.
44. Lee, Y.K.; Seo, C.S.; Lee, C.S.; Lee, K.S.; Kang, S.J.; Jahng, Y.; Chang, H.W.; Son, J.K., Inhibition of DNA topoisomerases I and II and cytotoxicity by lignans from Saururus chinensis. Arch. Pharm. Res., 2009, 32, 1409-1415.
45. Zhang, S.; Li, X.; Zhang, F.; Yang, P.; Gao, X.; Song, Q., Preparation of yuanhuacine and relative daphne diterpene esters from Daphne genkwa and structure-activity relationship of potent inhibitory activity against DNA topoisomerase I. Bioorg. Med. Chem., 2006, 14, 3888-3895.
46. Itoh, A.; Kumashiro, T.; Yamaguchi, M.; Nagakura, N.; Mizushina, Y.; Nishi, T.; Tanahashi, T., Indole alkaloids and other constituents of Rauwolfia serpentina. J. Nat. Prod., 2005, 68, 848-852. (Pubitemid 41017496)
47. Clericuzio, M.; Tabasso, S.; Bianco, M.A.; Pratesi, G.; Beretta, G.; Tinelli, S.; Zunino, F.; Vidari, G., Cucurbitane triterpenes from the fruiting bodies and cultivated mycelia of Leucopaxillus gentianeus. J. Nat. Prod., 2006, 69, 1796-1799. (Pubitemid 46144979)
48. Khan, Q.A.; Lu, J.; Hecht, S.M., Calothrixins, a new class of human DNA topoisomerase I poisons. J Nat Prod, 2009, 72, (3), 438-442.
49. Zhang, Z.; Wang, P.; Yuan, W.; Li, S., Steroids, alkaloids, and coumarins from Gelsemium sempervirens. Planta. Med., 2008, 74, 1818-1822.
50. Diaz-Carballo, D.; Malak, S.; Bardenheuer, W.; Freistuehler, M.; Peter Reusch, H., The contribution of plukenetione A to the anti-tumoral activity of Cuban propolis. Bioorg. Med. Chem., 2008, 16, 9635-9643.
51. Kanai, Y.; Ishiyama, D.; Senda, H.; Iwatani, W.; Takahashi, H.; Konno, H.; Tokumasu, S.; Kanazawa, S., Novel human topoisomerase I inhibitors, topopyrones A, B, C and D. I. Producing strain, fermentation, isolation, physico-chemical properties and biological activity. J. Antibiot., 2000, 53, 863-872.
52. Ishiyama, D.; Kanai, Y.; Senda, H.; Iwatani, W.; Konno, H.; Kanazawa, S., Novel human topoisomerase I inhibitors, topopyrones A, B, C and D. II. Structure elucidation. J. Antibiot., 2000, 53, 873-878.
53. Prudhomme, M., Rebeccamycin analogues as anti-cancer agents. Eur. J. Med. Chem., 2003, 38, 123-140. (Pubitemid 36288468)
54. Facompre, M.; Goossens, J.F.; Bailly, C., Apoptotic response of HL-60 human leukemia cells to the antitumor drug NB-506, a glycosylated indolocarbazole inhibitor of topoisomerase 1. Biochem. Pharmacol., 2001, 61, 299-310. (Pubitemid 32126668)
55. Ohkubo, M.; Kojiri, K.; Kondo, H.; Tanaka, S.; Kawamoto, H.; Nishimura, T.; Nishimura, I.; Yoshinari, T.; Arakawa, H.; Suda, H.; Morishima, H.; Nishimura, S., Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506. Bioorg. Med. Chem. Lett., 1999, 9, 1219-1224. (Pubitemid 29207435)
56. Ohkubo, M.; Nishimura, T.; Honma, T.; Nishimura, I.; Ito, S.; Yoshinari, T.; Suda, H.A.; Morishima, H.; Nishimura, S., Synthesis and biological activities of NB-506 analogues: Effects of the positions of two hydroxyl groups at the indole rings. Bioorg Med Chem Lett, 1999, 9, (23), 3307-3312.
57. Ohkubo, M.; Nishimura, T.; Kawamoto, H.; Nakano, M.; Honma, T.; Yoshinari, T.; Arakawa, H.; Suda, H.; Morishima, H.; Nishimura, S., Synthesis and biological activities of NB-506 analogues modified at the glucose group. Bioorg. Med. Chem. Lett., 2000, 10, 419-422. (Pubitemid 30153604)
58. Saif, M.W.; Diasio, R.B., Edotecarin: a novel topoisomerase I inhibitor. Clin. Colorectal. Cancer, 2005, 5, 27-36.
59. Hurwitz, H.I.; Cohen, R.B.; McGovren, J.P.; Hirawat, S.; Petros, W.P.; Natsumeda, Y.; Yoshinari, T., A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors. Cancer Chemother. Pharmacol., 2007, 59, 139-147. (Pubitemid 44796112)
60. Saif, M.W.; Sellers, S.; Diasio, R.B.; Douillard, J.Y., A phase I doseescalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors. Anticancer Drugs, 2010, 21, 716-723.
61. Balasubramanian, B.N.; St Laurent, D.R.; Saulnier, M.G.; Long, B.H.; Bachand, C.; Beaulieu, F.; Clarke, W.; Deshpande, M.; Eummer, J.; Fairchild, C.R.; Frennesson, D.B.; Kramer, R.; Lee, F.Y.; Mahler, M.; Martel, A.; Naidu, B.N.; Rose, W.C.; Russell, J.; Ruediger, E.; Solomon, C.; Stoffan, K.M.; Wong, H.; Wright, J.J.; Zimmermann, K.; Vyas, D.M., Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D- glucopyranosyl]-5H,13H-benzo [b]-thienyl[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)- dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor model. J. Med. Chem., 2004, 47, 1609-1612. (Pubitemid 38386629)
62. Saulnier, M.G.; Balasubramanian, B.N.; Long, B.H.; Frennesson, D.B.; Ruediger, E.; Zimmermann, K.; Eummer, J.T.; St Laurent, D.R.; Stoffan, K.M.; Naidu, B.N.; Mahler, M.; Beaulieu, F.; Bachand, C.; Lee, F.Y.; Fairchild, C.R.; Stadnick, L.K.; Rose, W.C.; Solomon, C.; Wong, H.; Martel, A.; Wright, J.J.; Kramer, R.; Langley, D.R.; Vyas, D.M., Discovery of a fluoroindolo[2,3-a] carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11. J. Med. Chem., 2005, 48, 2258-2261. (Pubitemid 40520515)
63. Zhang, G.; Shen, J.; Cheng, H.; Zhu, L.; Fang, L.; Luo, S.; Muller, M.T.; Lee, G.E.; Wei, L.; Du, Y.; Sun, D.; Wang, P.G., Syntheses and biological activities of rebeccamycin analogues with uncommon sugars. J. Med. Chem., 2005, 48, 2600-2611. (Pubitemid 40516449)
64. Routier, S.; Peixoto, P.; Merour, J.Y.; Coudert, G.; Dias, N.; Bailly, C.; Pierre, A.; Leonce, S.; Caignard, D.H., Synthesis and biological evaluation of novel naphthocarbazoles as potential anticancer agents. J. Med. Chem., 2005, 48, 1401-1413. (Pubitemid 40372209)
65. Routier, S.; Merour, J.Y.; Dias, N.; Lansiaux, A.; Bailly, C.; Lozach, O.; Meijer, L., Synthesis and biological evaluation of novel phenylcarbazoles as potential anticancer agents. J. Med. Chem., 2006, 49, 789-799. (Pubitemid 43158444)
66. Staker, B.L.; Feese, M.D.; Cushman, M.; Pommier, Y.; Zembower, D.; Stewart, L.; Burgin, A.B., Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J. Med. Chem., 2005, 48, 2336-2345. (Pubitemid 40516428)
67. Sunami, S.; Nishimura, T.; Nishimura, I.; Ito, S.; Arakawa, H.; Ohkubo, M., Synthesis and biological activities of topoisomerase I inhibitors, 6-arylmethylamino analogues of edotecarin. J. Med. Chem., 2009, 52, 3225-3237.
68. Diana, P.; Martorana, A.; Barraja, P.; Montalbano, A.; Dattolo, G.; Cirrincione, G.; Dall'acqua, F.; Salvador, A.; Vedaldi, D.; Basso, G.; Viola, G., Isoindolo[2,1-a]quinoxaline derivatives, novel potent antitumor agents with dual inhibition of tubulin polymerization and topoisomerase I. J. Med. Chem., 2008, 51, 2387-2399. (Pubitemid 351628500)
69. Bailly, C., Lamellarins, from A to Z: a family of anticancer marine pyrrole alkaloids. Curr. Med. Chem. Anticancer Agents, 2004, 4, 363-378. (Pubitemid 38923329)
70. Facompre, M.; Tardy, C.; Bal-Mahieu, C.; Colson, P.; Perez, C.; Manzanares, I.; Cuevas, C.; Bailly, C., Lamellarin D: a novel potent inhibitor of topoisomerase I. Cancer Res., 2003, 63, 7392-7399. (Pubitemid 37413481)
71. Marco, E.; Laine, W.; Tardy, C.; Lansiaux, A.; Iwao, M.; Ishibashi, F.; Bailly, C.; Gago, F., Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships. J. Med. Chem., 2005, 48, 3796-3807. (Pubitemid 40776854)
72. Tardy, C.; Facompre, M.; Laine, W.; Baldeyrou, B.; Garcia-Gravalos, D.; Francesch, A.; Mateo, C.; Pastor, A.; Jimenez, J.A.; Manzanares, I.; Cuevas, C.; Bailly, C., Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues. Bioorg. Med. Chem., 2004, 12, 1697-1712. (Pubitemid 38340766)
73. Ishibashi, F.; Tanabe, S.; Oda, T.; Iwao, M., Synthesis and structure-activity relationship study of lamellarin derivatives. J. Nat. Prod., 2002, 65, 500-504. (Pubitemid 34456932)
74. Pla, D.; Marchal, A.; Olsen, C.A.; Francesch, A.; Cuevas, C.; Albericio, F.; Alvarez, M., Synthesis and structure-activity relationship study of potent cytotoxic analogues of the marine alkaloid Lamellarin D. J. Med. Chem., 2006, 49, 3257-3268. (Pubitemid 43830523)
75. Ohta, T.; Fukuda, T.; Ishibashi, F.; Iwao, M., Design and synthesis of lamellarin D analogues targeting topoisomerase I. J. Org. Chem., 2009, 74, 8143-8153.
76. Chittchang, M.; Batsomboon, P.; Ruchirawat, S.; Ploypradith, P., Cytotoxicities and structure-activity relationships of natural and unnatural lamellarins toward cancer cell lines. ChemMedChem, 2009, 4, 457-465.
77. Kokoshka, J.M.; Capson, T.L.; Holden, J.A.; Ireland, C.M.; Barrows, L.R., Differences in the topoisomerase I cleavage complexes formed by camptothecin and wakayin, a DNA-intercalating marine natural product. Anticancer Drugs, 1996, 7, 758-765. (Pubitemid 26388766)
78. Hooper, G.J.; Davies-Coleman, M.T.; Kelly-Borges, M.; Coetzee, P.S., New alkaloids from South African Latrunculid sponge. Tetrahedron Lett., 1996, 37, 7135-7138. (Pubitemid 26305097)
79. Legentil, L.; Benel, L.; Bertrand, V.; Lesur, B.; Delfourne, E., Synthesis and antitumor characterization of pyrazolic analogues of the marine pyrroloquinoline alkaloids: wakayin and tsitsikammamines. J. Med. Chem., 2006, 49, 2979-2988.
80. Legentil, L.; Lesur, B.; Delfourne, E., Aza-analogues of the marine pyrroloquinoline alkaloids wakayin and tsitsikammamines: synthesis and topoisomerase inhibition. Bioorg. Med. Chem. Lett., 2006, 16, 427-429. (Pubitemid 41680640)
81. Li, T.K.; Bathory, E.; LaVoie, E.J.; Srinivasan, A.R.; Olson, W.K.; Sauers, R.R.; Liu, L.F.; Pilch, D.S., Human topoisomerase I poisoning by protoberberines: potential roles for both drug-DNA and drug-enzyme interactions. Biochemistry, 2000, 39, 7107-7116. (Pubitemid 30413099)
82. Basili, S.; Basso, G.; Faccio, A.; Granzhan, A.; Ihmels, H.; Moro, S.; Viola, G., Diazoniapolycyclic ions inhibit the activity of topoisomerase I and the growth of certain tumor cell lines. ChemMedChem, 2008, 3, 1671-1676.
83. Dallavalle, S.; Gattinoni, S.; Mazzini, S.; Scaglioni, L.; Merlini, L.; Tinelli, S.; Beretta, G.L.; Zunino, F., Synthesis and cytotoxic activity of a new series of topoisomerase I inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 1484-1489. (Pubitemid 351226518)
84. Scaglioni, L.; Mazzini, S.; Mondelli, R.; Dallavalle, S.; Gattinoni, S.; Tinelli, S.; Beretta, G.L.; Zunino, F.; Ragg, E., Interaction between double helix DNA fragments and a new topopyrone acting as human topoisomerase I poison. Bioorg. Med. Chem., 2009, 17, 484-491.
85. Suzuki, K.; Yahara, S.; Maehata, K.; Uyeda, M., Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba. J. Nat. Prod., 2001, 64, 204-207. (Pubitemid 32198347)
86. Suzuki, K.; Okawara, T.; Higashijima, T.; Yokomizo, K.; Mizushima, T.; Otsuka, M., Inhibitory activities against topoisomerase I and II by isoaurostatin derivatives and their structure-activity relationships. Bioorg. Med. Chem. Lett., 2005, 15, 2065-2068. (Pubitemid 40445470)
87. Chen, J.; Sun, Z.; Zhang, Y.; Zeng, X.; Qing, C.; Liu, J.; Li, L.; Zhang, H., Synthesis of gibberellin derivatives with anti-tumor bioactivities. Bioorg. Med. Chem. Lett., 2009, 19, 5496-5499.
88. Verma, R.P.; Hansch, C., Camptothecins: a SAR/QSAR study. Chem. Rev., 2009, 109, 213-235.
89. Pommier, Y.; Cushman, M., The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol. Cancer Ther., 2009, 8, 1008-1014.
90. Cushman, M.; Cheng, L., Stereoselective oxidation by thionyl chloride leadingto the indeno[1,2-c]isoquinoline system. J. Org. Chem., 1978, 43, 3781-3783.
91. Kohlhagen, G.; Paull, K.D.; Cushman, M.; Nagafuji, P.; Pommier, Y., Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol. Pharmacol., 1998, 54, 50-58. (Pubitemid 28337586)
92. Nagarajan, M.; Morrell, A.; Fort, B.C.; Meckley, M.R.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M., Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings. J. Med. Chem., 2004, 47, 5651-5661. (Pubitemid 39447262)
93. Morrell, A.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M., A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor. J. Med. Chem., 2006, 49, 7740-7753. (Pubitemid 46033665)
94. Morrell, A.; Placzek, M.; Parmley, S.; Antony, S.; Dexheimer, T.S.; Pommier, Y.; Cushman, M., Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization. J. Med. Chem., 2007, 50, 4419-4430. (Pubitemid 47378839)
95. Morrell, A.; Placzek, M.; Parmley, S.; Grella, B.; Antony, S.; Pommier, Y.; Cushman, M., Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors. J. Med. Chem., 2007, 50, 4388-4404. (Pubitemid 47378837)
96. Nagarajan, M.; Morrell, A.; Ioanoviciu, A.; Antony, S.; Kohlhagen, G.; Agama, K.; Hollingshead, M.; Pommier, Y.; Cushman, M., Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles. J. Med. Chem., 2006, 49, 6283-6289. (Pubitemid 44595205)
97. Ioanoviciu, A.; Antony, S.; Pommier, Y.; Staker, B.L.; Stewart, L.; Cushman, M., Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by Xray crystallographic analysis. J. Med. Chem., 2005, 48, 4803-4814. (Pubitemid 41033123)
98. Song, Y.; Shao, Z.; Dexheimer, T.S.; Scher, E.S.; Pommier, Y.; Cushman, M., Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors. J. Med. Chem., 2010, 53, 1979-1989.
99. Kiselev, E.; Dexheimer, T.S.; Pommier, Y.; Cushman, M., Design, synthesis, and evaluation of Dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents. J. Med. Chem., 2010, 53, 8716-8726.
100. Nagarajan, M.; Morrell, A.; Antony, S.; Kohlhagen, G.; Agama, K.; Pommier, Y.; Ragazzon, P.A.; Garbett, N.C.; Chaires, J.B.; Hollingshead, M.; Cushman, M., Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors. J. Med. Chem., 2006, 49, (17), 5129-5140. (Pubitemid 44260209)
101. Antony, S.; Agama, K.K.; Miao, Z.H.; Hollingshead, M.; Holbeck, S.L.; Wright, M.H.; Varticovski, L.; Nagarajan, M.; Morrell, A.; Cushman, M.; Pommier, Y., Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11Hindeno[ 1,2-c]isoquinoline) -6-propyla mino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity. Mol. Pharmacol., 2006, 70, 1109-1120. (Pubitemid 44268468)
102. Nguyen, C.H.; Fan, E.; Riou, J.F.; Bissery, M.C.; Vrignaud, P.; Lavelle, F.; Bisagni, E., Synthesis and biological evaluation of amino-substituted benzo[f]pyrido[4,3-b] and pyrido[3,4-b]quinoxalines: a new class of antineoplastic agents. Anticancer Drug Des., 1995, 10, 277-297.
103. Singh, M.; Tandon, V., Synthesis and biological activity of novel inhibitors of topoisomerase I: 2-aryl-substituted 2-bis-1H-benzimidazoles. Eur. J. Med. Chem., 2011, 46, 659-669.
104. Pommier, Y.; Pourquier, P.; Fan, Y.; Strumberg, D., Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1998, 1400, (1-3), 83-105.
105. Chaudhuri, P.; Majumder, H.K.; Bhattacharya, S., Synthesis, DNA binding, and Leishmania topoisomerase inhibition activities of a novel series of anthra[ 1,2-d]imidazole-6,11-dione derivatives. J. Med. Chem., 2007, 50, 2536-2540. (Pubitemid 46799266)
106. Zhao, L.X.; Kim, T.S.; Ahn, S.H.; Kim, T.H.; Kim, E.K.; Cho, W.J.; Choi, H.; Lee, C.S.; Kim, J.A.; Jeong, T.C.; Chang, C.J.; Lee, E.S., Synthesis, topoisomerase I inhibition and antitumor cytotoxicity of 2 2′:6′, 2″-, 2,2′:6′,3″- and 2 2′:6′,4″- terpyridine derivatives. Bioorg. Med. Chem. Lett., 2001, 11, 2659-2662. (Pubitemid 32823378)
107. Zhao, L.X.; Moon, Y.S.; Basnet, A.; Kim, E.K.; Jahng, Y.; Park, J.G.; Jeong, T.C.; Cho, W.J.; Choi, S.U.; Lee, C.O.; Lee, S.Y.; Lee, C.S.; Lee, E.S., Synthesis, topoisomerase I inhibition and structure-activity relationship study of 2,4,6-trisubstituted pyridine derivatives. Bioorg. Med. Chem. Lett., 2004, 14, 1333-1337. (Pubitemid 38232668)
108. Son, J.K.; Zhao, L.X.; Basnet, A.; Thapa, P.; Karki, R.; Na, Y.; Jahng, Y.; Jeong, T.C.; Jeong, B.S.; Lee, C.S.; Lee, E.S., Synthesis of 2,6-diarylsubstituted pyridines and their antitumor activities. Eur. J. Med. Chem., 2008, 43, 675-682. (Pubitemid 351446141)
109. Basnet, A.; Thapa, P.; Karki, R.; Na, Y.; Jahng, Y.; Jeong, B.S.; Jeong, T.C.; Lee, C.S.; Lee, E.S., 2,4,6-Trisubstituted pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship. Bioorg. Med. Chem., 2007, 15, 4351-4359. (Pubitemid 46777301)
110. Basnet, A.; Thapa, P.; Karki, R.; Choi, H.; Choi, J.H.; Yun, M.; Jeong, B.S.; Jahng, Y.; Na, Y.; Cho, W.J.; Kwon, Y.; Lee, C.S.; Lee, E.S., 2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study. Bioorg. Med. Chem. Lett., 2010, 20, 42-47.
111. Thapa, P.; Karki, R.; Thapa, U.; Jahng, Y.; Jung, M.J.; Nam, J.M.; Na, Y.; Kwon, Y.; Lee, E.S., 2-Thienyl-4-furyl-6-aryl pyridine derivatives: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study. Bioorg. Med. Chem., 2010, 18, 377-386.
112. Karki, R.; Thapa, P.; Kang, M.J.; Jeong, T.C.; Nam, J.M.; Kim, H.L.; Na, Y.; Cho, W.J.; Kwon, Y.; Lee, E.S., Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines. Bioorg. Med. Chem., 2010, 18, 3066-3077.
113. Martinez, V.; Burgos, C.; Alvarez-Builla, J.; Fernandez, G.; Domingo, A.; Garcia-Nieto, R.; Gago, F.; Manzanares, I.; Cuevas, C.; Vaquero, J.J., Benzo[f]azino[2,1-a]phthalazinium cations: novel DNA intercalating chromophores with antiproliferative activity. J. Med. Chem., 2004, 47, 1136-1148. (Pubitemid 38229115)
114. Shaikh, I.A.; Johnson, F.; Grollman, A.P., Streptonigrin. 1. Structure-activity relationships among simple bicyclic analogues. Rate dependence of DNA degradation on quinone reduction potential. J. Med. Chem., 1986, 29, 1329-1340. (Pubitemid 16034617)
115. Suh, M.E.; Kang, M.J.; Park, S.Y., The 3-D QSAR study of anticancer 1-Nsubstituted imidazo- and pyrrolo-quinoline-4,9-dione derivatives by CoMFA and CoMSIA. Bioorg. Med. Chem., 2001, 9, 2987-2991.
116. Cheng, Y.; An, L.K.; Wu, N.; Wang, X.D.; Bu, X.Z.; Huang, Z.S.; Gu, L.Q., Synthesis, cytotoxic activities and structure-activity relationships of topoisomerase I inhibitors: indolizinoquinoline-5,12-dione derivatives. Bioorg. Med. Chem., 2008, 16, 4617-4625. (Pubitemid 351539023)
117. Yang, P.; Yang, Q.; Qian, X.; Cui, J., Novel synthetic isoquinolino[5,4-ab]phenazines: inhibition toward topoisomerase I, antitumor and DNA photo-cleaving activities. Bioorg. Med. Chem., 2005, 13, 5909-5914. (Pubitemid 41399899)
118. Gao, C.; Liu, F.; Luan, X.; Tan, C.; Liu, H.; Xie, Y.; Jin, Y.; Jiang, Y., Novel synthetic 2-amino-10-(3,5-dimethoxy)benzyl-9(10H)-acridinone derivatives as potent DNA-binding antiproliferative agents. Bioorg. Med. Chem., 2010, 18, 7507-7514.
119. Esteves-Souza, A.; Pissinate, K.; Nascimento Mda, G.; Grynberg, N.F.; Echevarria, A., Synthesis, cytotoxicity, and DNA-topoisomerase inhibitory activity of new asymmetric ureas and thioureas. Bioorg. Med. Chem., 2006, 14, 492-499. (Pubitemid 41767609)
120. McKnight, R.E.; Gleason, A.B.; Keyes, J.A.; Sahabi, S., Binding mode and affinity studies of DNA-binding agents using topoisomerase I DNA unwinding assay. Bioorg. Med. Chem. Lett., 2007, 17, 1013-1017. (Pubitemid 46177615)
121. Schneider, G.; Neidhart, W.; Giller, T.; Schmid, G., "Scaffold- Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. Angew. Chem. Int. Ed. Engl., 1999, 38, 2894-2896. (Pubitemid 29479958)
122. Cinelli, M.A.; Morrell, A.; Dexheimer, T.S.; Scher, E.S.; Pommier, Y.; Cushman, M., Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors. J. Med. Chem., 2008, 51, 4609-4619.
123. Cinelli, M.A.; Morrell, A.E.; Dexheimer, T.S.; Agama, K.; Agrawal, S.; Pommier, Y.; Cushman, M., The structure-activity relationships of A-ringsubstituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode. Bioorg. Med. Chem., 2010, 18, 5535-5552.
124. Ruchelman, A.L.; Singh, S.K.; Ray, A.; Wu, X.H.; Yang, J.M.; Li, T.K.; Liu, A.; Liu, L.F.; LaVoie, E.J., 5H-Dibenzo[c,h]1,6-naphthyridin-6-ones: novel topoisomerase I-targeting anticancer agents with potent cytotoxic activity. Bioorg. Med. Chem., 2003, 11, 2061-2073. (Pubitemid 36379023)
125. Ruchelman, A.L.; Singh, S.K.; Wu, X.; Ray, A.; Yang, J.M.; Li, T.K.; Liu, A.; Liu, L.F.; LaVoie, E.J., Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435. Bioorg. Med. Chem. Lett., 2002, 12, 3333-3336. (Pubitemid 35248243)
126. Li, T.K.; Houghton, P.J.; Desai, S.D.; Daroui, P.; Liu, A.A.; Hars, E.S.; Ruchelman, A.L.; LaVoie, E.J.; Liu, L.F., Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res., 2003, 63, 8400-8407. (Pubitemid 37549495)
127. Meng, F.; Nguyen, X.T.; Cai, X.; Duan, J.; Matteucci, M.; Hart, C.P., ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulation. Anticancer Drugs, 2007, 18, 435-445. (Pubitemid 46712407)
128. Ruchelman, A.L.; Houghton, P.J.; Zhou, N.; Liu, A.; Liu, L.F.; LaVoie, E.J., 5-(2-aminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: variation of n-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance. J. Med. Chem., 2005, 48, 792-804. (Pubitemid 40209101)
129. Feng, W.; Satyanarayana, M.; Tsai, Y.C.; Liu, A.A.; Liu, L.F.; LaVoie, E.J., Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9- methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]di benzo[c,h][1,6] naphthyridin-6-one iodide. Eur. J. Med. Chem., 2009, 44, 3433-3438.
130. Satyanarayana, M.; Feng, W.; Cheng, L.; Liu, A.A.; Tsai, Y.C.; Liu, L.F.;
131. Zhu, S.; Ruchelman, A.L.; Zhou, N.; Liu, A.; Liu, L.F.; LaVoie, E.J., 6-Substituted 6H-dibenzo[c,h][2,6]naphthyridin-5-ones: reversed lactam analogues of ARC-111 with potent topoisomerase I-targeting activity and cytotoxicity. Bioorg. Med. Chem., 2006, 14, 3131-3143.
132. Ruchelman, A.L.; Singh, S.K.; Ray, A.; Wu, X.; Yang, J.M.; Zhou, N.; Liu, A.; Liu, L.F.; LaVoie, E.J., 11H-Isoquino[4,3-c]cinnolin-12-ones; novel anticancer agents with potent topoisomerase I-targeting activity and cytotoxicity. Bioorg. Med. Chem., 2004, 12, 795-806. (Pubitemid 38173061)
133. Feng, W.; Satyanarayana, M.; Tsai, Y.C.; Liu, A.A.; Liu, L.F.; LaVoie, E.J., 12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents. Bioorg. Med. Chem., 2009, 17, 2877-2885.
134. Feng, W.; Satyanarayana, M.; Tsai, Y.C.; Liu, A.A.; Liu, L.F.; LaVoie, E.J., 11-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine derivatives as novel topoisomerase I-targeting agents. Bioorg. Med. Chem., 2008, 16, 8598-8606.
135. You, Q.D.; Li, Z.Y.; Huang, C.H.; Yang, Q.; Wang, X.J.; Guo, Q.L.; Chen, X.G.; He, X.G.; Li, T.K.; Chern, J.W., Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification. J. Med. Chem., 2009, 52, 5649-5661.
136. Hranjec, M.; Kralj, M.; Piantanida, I.; Sedic, M.; Suman, L.; Pavelic, K.; Karminski-Zamola, G., Novel cyano- and amidino-substituted derivatives of styryl-2-benzimidazoles and benzimidazo[1,2-a]quinolines. Synthesis, photochemical synthesis, DNA binding, and antitumor evaluation, part 3. J. Med. Chem., 2007, 50, 5696-5711. (Pubitemid 350106024)
137. Hranjec, M.; Piantanida, I.; Kralj, M.; Suman, L.; Pavelic, K.; Karminski-Zamola, G., Novel amidino-substituted thienyl- and furylvinylbenzimidazole: derivatives and their photochemical conversion into corresponding diazacyclopenta[ c]fluorenes. synthesis, interactions with DNA and RNA, and antitumor evaluation. 4. J. Med. Chem., 2008, 51, 4899-4910.
138. Shchekotikhin, A.E.; Dezhenkova, L.G.; Susova, O.Y.; Glazunova, V.A.; Luzikov, Y.N.; Sinkevich, Y.B.; Buyanov, V.N.; Shtil, A.A.; Preobrazhenskaya, M.N., Naphthoindole-based analogues of tryptophan and tryptamine: synthesis and cytotoxic properties. Bioorg. Med. Chem., 2007, 15, 2651-2659. (Pubitemid 46367701)
139. Shi, W.; Marcus, S.L.; Lowary, T.L., Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans. Bioorg. Med. Chem., 2011, 19, 603-612.
140. Kang, D.H.; Kim, J.S.; Jung, M.J.; Lee, E.S.; Jahng, Y.; Kwon, Y.; Na, Y., New insight for fluoroquinophenoxazine derivatives as possibly new potent topoisomerase I inhibitor. Bioorg. Med. Chem. Lett., 2008, 18, 1520-1524. (Pubitemid 351227458)
141. Goodell, J.R.; Madhok, A.A.; Hiasa, H.; Ferguson, D.M., Synthesis and evaluation of acridine- and acridone-based anti-herpes agents with topoisomerase activity. Bioorg. Med. Chem., 2006, 14, 5467-5480. (Pubitemid 43994481)
142. Goodell, J.R.; Ougolkov, A.V.; Hiasa, H.; Kaur, H.; Remmel, R.; Billadeau, D.D.; Ferguson, D.M., Acridine-based agents with topoisomerase II activity inhibit pancreatic cancer cell proliferation and induce apoptosis. J. Med. Chem., 2008, 51, 179-182.
143. Galvez-Peralta, M.; Hackbarth, J.S.; Flatten, K.S.; Kaufmann, S.H.; Hiasa, H.; Xing, C.; Ferguson, D.M., On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents. Bioorg. Med. Chem. Lett., 2009, 19, 4459-4462.
144. Denny, W.A.; Baguley, B.C., Dual topoisomerase I/II inhibitors in cancer therapy. Curr. Top. Med. Chem., 2003, 3, 339-353.
145. Rewcastle, G.W.; Denny, W.A.; Baguley, B.C., Potential antitumor agents. 51. Synthesis and antitumor activity of substituted phenazine-1-carboxamides. J. Med. Chem., 1987, 30, 843-851. (Pubitemid 17119530)
146. Vicker, N.; Burgess, L.; Chuckowree, I.S.; Dodd, R.; Folkes, A.J.; Hardick, D.J.; Hancox, T.C.; Miller, W.; Milton, J.; Sohal, S.; Wang, S.; Wren, S.P.; Charlton, P.A.; Dangerfield, W.; Liddle, C.; Mistry, P.; Stewart, A.J.; Denny, W.A., Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents. J. Med. Chem., 2002, 45, 721-739. (Pubitemid 34145719)
147. Ishida, K.; Asao, T., Self-association and unique DNA binding properties of the anti-cancer agent TAS-103, a dual inhibitor of topoisomerases I and II. Biochim. Biophys. Acta, 2002, 1587, 155-163. (Pubitemid 34655785)
148. Padget, K.; Stewart, A.; Charlton, P.; Tilby, M.J.; Austin, C.A., An investigation into the formation of N-[2-(dimethylamino)ethyl]acridine-4- carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]-3-hydroxy-7Hindeno[ 2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells. Biochem. Pharmacol., 2000, 60, 817-821. (Pubitemid 30621666)
149. Marzaro, G.; Dalla Via, L.; Toninello, A.; Guiotto, A.; Chilin, A., Benzoquinazoline derivatives as new agents affecting DNA processing. Bioorg. Med. Chem., 2011, 19, 1197-1204.
150. Chen, Y.L.; Hung, H.M.; Lu, C.M.; Li, K.C.; Tzeng, C.C., Synthesis and anticancer evaluation of certain indolo[2,3-b]quinoline derivatives. Bioorg. Med. Chem., 2004, 12,6539-6546.
151. Lu, C.M.; Chen, Y.L.; Chen, H.L.; Chen, C.A.; Lu, P.J.; Yang, C.N.; Tzeng, C.C., Synthesis and antiproliferative evaluation of certain indolo[3,2-c]quinoline derivatives. Bioorg. Med. Chem., 2010, 18, 1948-1957.
152. Tseng, C.H.; Chen, Y.L.; Chung, K.Y.; Cheng, C.M.; Wang, C.H.; Tzeng, C.C., Synthesis and antiproliferative evaluation of 6-arylindeno[1,2-c]quinoline derivatives. Bioorg. Med. Chem., 2009, 17, 7465-7476.
153. Tseng, C.H.; Chen, Y.L.; Lu, P.J.; Yang, C.N.; Tzeng, C.C., Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Bioorg. Med. Chem., 2008, 16, 3153-3162.
154. Tseng, C.H.; Tzeng, C.C.; Yang, C.L.; Lu, P.J.; Chen, H.L.; Li, H.Y.; Chuang, Y.C.; Yang, C.N.; Chen, Y.L., Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Part 2. J. Med. Chem., 2010, 53, 6164-6179.
155. Kolb, P.; Rosenbaum, D.M.; Irwin, J.J.; Fung, J.J.; Kobilka, B.K.; Shoichet, B.K., Structure-based discovery of beta2-adrenergic receptor ligands. Proc. Natl. Acad. Sci. U S A., 2009, 106, 6843-6848.
156. Li, H.; Huang, J.; Chen, L.; Liu, X.; Chen, T.; Zhu, J.; Lu, W.; Shen, X.; Li, J.; Hilgenfeld, R.; Jiang, H., Identification of novel falcipain-2 inhibitors as potential antimalarial agents through structure-based virtual screening. J. Med. Chem., 2009, 52, 4936-4940.
157. Shoichet, B.K., Virtual screening of chemical libraries. Nature, 2004, 432, 862-865. (Pubitemid 40037142)
158. Redinbo, M.R.; Stewart, L.; Kuhn, P.; Champoux, J.J.; Hol, W.G., Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science, 1998, 279, 1504-1513. (Pubitemid 28217069)
159. Staker, B.L.; Hjerrild, K.; Feese, M.D.; Behnke, C.A.; Burgin, A.B., Jr.; Stewart, L., The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. U S A., 2002, 99, 15387-15392. (Pubitemid 35403944)
160. Dong, G.; Sheng, C.; Wang, S.; Miao, Z.; Yao, J.; Zhang, W., Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents. J. Med. Chem., 2010, 53, 7521-7531.
161. Jones, G.; Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R., Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol., 1997, 267, 727-748. (Pubitemid 27170693)
162. Dong, K.C.; Berger, J.M., Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature, 2007, 450, 1201-1205.
163. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46, 3-26. (Pubitemid 33653411)
164. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H., A 'rule of three' for fragmentbased lead discovery? Drug Discov. Today, 2003, 8, 876-877.
165. van de Waterbeemd, H.; Gifford, E., ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov., 2003, 2, 192-204. (Pubitemid 37361664)
166. Yu, H.; Adedoyin, A., ADME-Tox in drug discovery: integration of experimental and computational technologies. Drug Discov. Today, 2003, 8, 852-861. (Pubitemid 37083343)
167. Cho, H.J.; Jung, M.J.; Kwon, Y.; Na, Y., Oxiranylmethyloxy or thiiranylmethyloxy-azaxanthones and -acridone analogues as potential topoisomerase I inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 6766-6769.
168. Janovec, L.; Kozurkova, M.; Sabolova, D.; Ungvarsky, J.; Paulikova, H.; Plsikova, J.; Vantova, Z.; Imrich, J., Cytotoxic 3,6-bis((imidazolidinone)imino) acridines: Synthesis, DNA binding and molecular modeling. Bioorg. Med. Chem., 2011, 19, 1790-1801.